Precision BioSciences Inc
F:PBS0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Precision BioSciences Inc
F:PBS0
|
US |
|
E
|
EarthRenew Inc
F:WIMN
|
CA |
|
Critical Elements Lithium Corp
F:F12
|
CA |
|
T
|
TeamViewer AG
F:TMV
|
DE |
Precision BioSciences Inc
Precision BioSciences is a biotechnology company that builds gene-editing medicines using its ARCUS platform. ARCUS is the company’s main tool for cutting DNA in precise places, which it uses to design therapies that can fix, disable, or replace faulty genes. Rather than selling a consumer product, the company develops drug candidates for serious diseases where genetic editing could address the root cause. Its main customers are not patients directly but pharmaceutical partners, research collaborators, and eventually healthcare providers and patients if its therapies reach the market. Precision can make money through collaboration deals, licensing its editing technology, and by advancing its own drug programs. In gene therapy, the company’s value comes from being the engineering layer that helps turn difficult genetic ideas into testable medicines. What makes its business different is that it sits at the intersection of drug development and genome engineering. Many biotech firms focus on one disease area, but Precision’s core asset is the editing platform itself, which can be applied across different genetic targets. That means its long-term success depends on both the strength of its science and its ability to turn that platform into partner deals or approved therapies.
Precision BioSciences is a biotechnology company that builds gene-editing medicines using its ARCUS platform. ARCUS is the company’s main tool for cutting DNA in precise places, which it uses to design therapies that can fix, disable, or replace faulty genes. Rather than selling a consumer product, the company develops drug candidates for serious diseases where genetic editing could address the root cause.
Its main customers are not patients directly but pharmaceutical partners, research collaborators, and eventually healthcare providers and patients if its therapies reach the market. Precision can make money through collaboration deals, licensing its editing technology, and by advancing its own drug programs. In gene therapy, the company’s value comes from being the engineering layer that helps turn difficult genetic ideas into testable medicines.
What makes its business different is that it sits at the intersection of drug development and genome engineering. Many biotech firms focus on one disease area, but Precision’s core asset is the editing platform itself, which can be applied across different genetic targets. That means its long-term success depends on both the strength of its science and its ability to turn that platform into partner deals or approved therapies.
